Browsing Tag
Oncology
318 posts
Lantern Pharma highlights AI-powered cancer research platforms during UNT’s first AI for Biology & Medicine symposium
Find out how Lantern Pharma is redefining AI-driven cancer drug development with predictBBB.ai and LBx-AI at UNT’s inaugural AI4BM symposium.
GSK’s B7-H3 ADC secures EU orphan drug status as it accelerates global lung cancer trials
GSK’s B7-H3-targeted ADC GSK’227 receives EU Orphan Drug Designation for small-cell lung cancer. Learn how it fits into the company’s expanding global trial program.
Is GSK stock gearing up for a breakout? Q3 2025 results beat, guidance raised, CEO exits on a high
GSK upgrades 2025 guidance after strong Q3 results, driving a 6.57% stock surge. Find out how Specialty Medicines and Oncology powered this breakout.
Merck’s kidney cancer breakthrough hits one target—Will it be enough to change how doctors treat RCC?
Merck and Eisai’s new kidney cancer combination met a key Phase 3 goal. Discover what it means for patients, investors, and the oncology landscape.
How Celcuity Inc.’s gedatolisib trial results sent its stock soaring 46% in a single morning
Celcuity stock surged 46% after Phase 3 trial data showed strong efficacy for gedatolisib in HR+/HER2- breast cancer. Find out what this means for investors.
Ivonescimab plus chemotherapy cuts disease progression risk by 40% in first-line squamous NSCLC, outperforming PD-1 rival in Akeso’s HARMONi-6 trial
Find out how Akeso’s ivonescimab plus chemotherapy achieved a 40 % risk reduction over a PD-1 inhibitor combo in squamous NSCLC—and why it’s shaking up the global oncology market!
Pfizer data reveal sustained survival with BRAFTOVI + MEKTOVI in rare lung cancer subtype
Find out how Pfizer’s BRAFTOVI + MEKTOVI combination is redefining survival for BRAF V600E-mutant lung cancer and what it means for Pfizer’s oncology strategy.
Incyte’s dual-target antibody and KRAS G12D drug show early promise in hard-to-treat colorectal and pancreatic cancers
Find out how Incyte’s Phase 1 cancer data could transform treatment for colorectal and pancreatic patients—read what’s driving investor optimism today!
NextCure brings Simcere Zaiming’s SIM0505 to U.S. trials as ADC race accelerates in oncology
Find out how NextCure and Simcere Zaiming are expanding SIM0505’s Phase 1 program into the U.S. and redefining the future of ADC collaboration.
Tempus joins forces with Whitehawk Therapeutics to power next-gen biomarker-based oncology trials
Find out how Tempus and Whitehawk are using AI and real-world data to transform biomarker-driven oncology—discover the collaboration’s science and market impact.